Sirpa Jalkanen

This inventor holds 14 USPTO granted patents and 5 published patent applications, plus 6 CIPO patents and 8 EPO patents. Top assignees: Faron Pharmaceuticals Oy, Biotie Therapies Corporation, Faron Ventures Oy. Active years: 1996-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sirpa Jalkanen. Retrieved from https://idiyas.com/inventor/sirpa-jalkanen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 92.9

CIPO Patents = 6 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 7)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 33(Granted Patents)

Location History:

20760 Piispanristi, FI (1996 - 2000)
Piispanristi, FI (2008 - 2020)

Company Filing History:

8 out of 16

Faron Pharmaceuticals Oy

patents

1 out of 28

Biotie Therapies Corporation

4. 4 out of 834,601

Other

patents

Years Active: 1996-2020

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10526607 - Cell and therapeutical and diagnostical methods based thereon (2020-01-07),

2. 10247730 - Method for determining acute respiratory distress syndrome (ARDS) related biomarkers, a method to monitor the development and treatment of ARDS in a patient (2019-04-02),

3. 8975081 - Biomarker for monitoring development of diseases and assessing the efficacy of therapies (2015-03-10),

4. 8722045 - Cell and therapeutical and diagnostical methods based thereon (2014-05-13),

5. 8138151 - Peptides (2012-03-20),

6. 8119651 - Compositions useful especially for treatment or prevention of metabolic syndrome (2012-02-21),

7. 7910097 - Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof (2011-03-22),

8. 7727521 - Method of ameliorating multi-organ failure resulting from ischemic reperfusion injury (2010-06-01),

9. 7534423 - Method for inducing an elevated level of adenosine in an individual (2009-05-19),

10. 7354577 - Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof (2008-04-08),

11. 6066321 - Method for antagonizing vascular adhesion protein-1 (VAP-1)-mediated (2000-05-23),

12. 5616468 - Compositions and diagnostic methods using monoclonal antibodies against (1997-04-01),

13. 5580780 - Vascular adhesion protein-(VAP-1) and VAP-1-specific antibodies (1996-12-03),

14. 5512442 - Detection of vascular adhesion protein-1 (VAP-1) (1996-04-30),

Title: The Innovative Journey of Sirpa Jalkanen

Introduction: Sirpa Jalkanen, a pioneering inventor hailing from Piispanristi, Finland, has made significant contributions to the field of biotechnology with her groundbreaking inventions.

Latest Patents: Sirpa Jalkanen's latest patents focus on novel methods for targeted drug delivery in cancer treatment, showcasing her commitment to advancing medical technology.

Career Highlights: With a distinguished career spanning over two decades, Sirpa Jalkanen has held key research positions in leading biotech companies, where she has spearheaded projects that have revolutionized the industry.

Collaborations: Throughout her career, Sirpa Jalkanen has collaborated with renowned scientists and researchers from top universities and research institutions worldwide, fostering a culture of innovation and knowledge exchange.

Conclusion: Sirpa Jalkanen's relentless pursuit of innovation and her passion for improving healthcare through technology make her a true trailblazer in the field of biotechnology.

Profile summary based on public USPTO records.